Valeant Pharma (VRX) Swings to Q3 Loss; Declares $1.00 Special Dividend; Authorizes $1.5B Stock Buyback

November 4, 2010 7:15 AM

Valeant Pharmaceuticals (NYSE: VRX) reports Q3 loss of $1.27, versus $0.25 reported for the same period a year ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found